IP Library Granted Patent US 12673146
Granted Patent B2
US 12673146 · App. 17/146,161 · Granted Jul 7, 2026

Plasmapheresis device

Inventor: Isaac Eliaz (Santa Rosa, CA)
Assignee: ELIAZ THERAPEUTIC, INC.
A61M1/3496A61M1/3403A61M1/3472A61M1/3486A61M1/3672A61M1/3679A61M1/3693A61M1/3696A61M2202/0445A61M2202/09A61M2230/005A61M2230/04A61M2230/06A61M2230/205A61M2230/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12673146
App. No.
17/146,161
Granted
Jul 7, 2026
Kind
B2
Abstract

A plasmapheresis device includes a column or other flow mechanism in which plasma lows following separation of the plasma from cellular components like blood cells, platelets and the like. The column includes a moiety, such as an antibody, which selectively binds to galectin-3. By removing galectin-3 from the blood stream of a mammal by at least 10%, improvements in the treatment of inflammation, suppression of the formation of fibroses, and a variety of cancer treatments can be effected or improved. The device provides tor multiple columns to remove a variety of elements but includes one which selectively removes galectin-3 from the blood flow. Other agents may be added to the plasma before recombination with the cellular components of the blood, and before returning the recombined flow to the patient.

Claims (7)

1 . A device for performing plasmapheresis, comprising:

a first conduit through which blood drawn from a mammalian patient travels under the influence of a pump;

a separator for separating cellular components of said blood from plasma;

a column device through which said plasma flows, which said column device selectively removes a plasma component, wherein said plasma component is selected from the group consisting of low-density lipoprotein, lipoprotein-associated phospholipase A2 and lipoprotein A,

a second column device for selective withdrawal of galectin-3 from said plasma, wherein said plasma encounters said first column device and second column device in any order,

a second conduit which receives said treated plasma following passage in said column devices and wherein said treated plasma is combined with blood cells separated in said separator prior to return to said mammalian patient;

wherein said first and second conduits provide for continuous flow of said blood and plasma from said patient and return to said mammalian patient.